A Phase I Study of Multi-Hla-Binding Peptides Derived From Heat Shock Protein 70/Glypican-3 and a Novel Combination Adjuvant of hLAG-3Ig and Poly-Iclc for Patients With Metastatic Gastrointestinal Cancers: YNP01 Trial

Cancer Immunology, Immunotherapy - Germany
doi 10.1007/s00262-020-02518-7
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

Vaccination With LAG-3Ig (IMP321) and Peptides Induces Specific CD4 and CD8 T-Cell Responses in Metastatic Melanoma Patients--Report of a Phase I/IIa Clinical Trial

Clinical Cancer Research
Cancer ResearchOncology
2015English

Phase I Pharmacokinetic-Pharmacodynamic Study of 17-(Allylamino)-17-Demethoxygeldanamycin (17AAG, NSC 330507), a Novel Inhibitor of Heat Shock Protein 90, in Patients With Refractory Advanced Cancers

Clinical Cancer Research
Cancer ResearchOncology
2005English

Phase I Trial With a Combination of Docetaxel and 153Sm-Lexidronam in Patients With Castration-Resistant Metastatic Prostate Cancer

Urologic Oncology: Seminars and Original Investigations
OncologyUrology
2011English

Phase I Trial of FOLFIRI in Combination With Sorafenib and Bevacizumab in Patients With Advanced Gastrointestinal Malignancies.

Journal of Clinical Oncology
Cancer ResearchMedicineOncology
2014English

First-In-Man Phase I Study of GC33, a Novel Recombinant Humanized Antibody Against Glypican-3, in Patients With Advanced Hepatocellular Carcinoma

Clinical Cancer Research
Cancer ResearchOncology
2013English

A Phase I Clinical Trial of Vaccination With KIF20A-derived Peptide in Combination With Gemcitabine for Patients With Advanced Pancreatic Cancer

Journal of immunotherapy (Hagerstown, Md. : 1997)
Cancer ResearchAllergyImmunologyPharmacology
2014English

Heat Shock Protein Peptide Complex-96 Vaccination for Newly Diagnosed Glioblastoma: A Phase I, Single-Arm Trial

JCI insight
Medicine
2018English

Efficacy and Safety of TAS-116, an Oral Inhibitor of Heat Shock Protein 90, in Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumour Refractory to Imatinib, Sunitinib and Regorafenib: A Phase II, Single-Arm Trial

European Journal of Cancer
Cancer ResearchOncology
2019English

A Phase I Trial of Combination Trastuzumab, Lapatinib, and Bevacizumab in Patients With Advanced Cancer

Investigational New Drugs
OncologyPharmacology
2014English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy